Genscript Biotech Corporation (GNNSF) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Nanjing, 중국. 현재 CEO는 Weihui Shao.
GNNSF 을(를) 보유 IPO 날짜 2017-09-28, 5,568 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $3.1B.
Genscript Biotech Corporation is a global life science company founded in 2002 and headquartered in Nanjing, China, serving customers across North America, Europe, Asia Pacific, and internationally. The company operates through four primary segments: Life Science Services and Products, which provides gene synthesis, protein engineering, antibody development, and molecular diagnostics tools for research and drug discovery; Biologics Development Services, offering antibody drug development, gene therapy, and cell therapy development for pharmaceutical and biotech clients; Industrial Synthetic Biology Products, which manufactures microbial strains and industrial enzymes for food, pharmaceutical, and chemical industries; and Cell Therapy, focusing on chimeric antigen receptor T-cell therapies for cancer treatment. Through these integrated business segments, Genscript delivers comprehensive research products and development services that support basic biology studies, pharmaceutical discovery, disease diagnostics, and therapeutic development.
